Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03772249
Other study ID # DCR-HBVS-101
Secondary ID U1111-1220-7021
Status Completed
Phase Phase 1
First received
Last updated
Start date December 28, 2018
Est. completion date July 12, 2022

Study information

Verified date September 2022
Source Dicerna Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

DCR-HBVS will be evaluated for safety and efficacy in healthy volunteers and chronic hepatitis B patients.


Description:

DCR HBVS is being developed for the treatment of chronic hepatitis B (CHB) in adults. The study will be conducted in 3 parts, a single ascending-dose (SAD) phase in normal healthy volunteers (Group A), a single-dose (SD) phase in patients with CHB (Group B), and a multiple ascending-dose (MAD) phase in patients with CHB (Group 1c-3c). Cohort 4c is a single ascending dose with a possible duration of up to 48 weeks. Cohort 5c is a multiple dose cohort with a possible duration of up to 72 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date July 12, 2022
Est. primary completion date July 12, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy at the time of screening as determined by medical evaluation. - Capable of giving informed consent. - 12-lead ECG within normal limits or with no clinically significant abnormalities. - Negative screen for alcohol or drugs of abuse. - Non-smokers for at least 3 months with a negative urinary cotinine concentration at screening. - BMI within range 18.0 - 32.0 kg/m2 (inclusive). - Female participants not pregnant, not breastfeeding, and not of childbearing potential or willing to follow contraceptive guidance. - Chronic hepatitis B infection (Group B and C only). - Clinical history compatible with compensated liver disease with no evidence of cirrhosis (Group B and C only). - Continuously on nucleotides (NUC) therapy for at least 12 weeks prior to screening (Group C only). Exclusion Criteria: - History of any medical condition that may interfere with the absorption, distribution, or elimination of study drug. - Poorly controlled or unstable hypertension. - History of diabetes mellitus treated with insulin or hypoglycemic agents. - History of asthma requiring hospital admission within the preceding 12 months. - Evidence of G-6-PD deficiency. - Currently poorly controlled endocrine conditions, excluding thyroid conditions. - History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc. - Clinically relevant surgical history. - Use of prescription medications (excluding contraception for women) within 4 weeks prior to the administration of study intervention. - Use of clinically relevant over-the-counter medication or supplements (excluding routine vitamins) within 7 days of first dosing. - Has received an investigational agent within the 3 months prior to dosing or is in follow-up of another study. - Antiviral therapy (other than entecavir or tenofovir) within 3 months of screening or treatment with interferon in the last 3 years (Group B and C only). - Use within the last 6 months of anticoagulants or systemically administered corticosteroids, immunomodulators, or immunosuppressants (Group B and C only).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DCR-HBVS
DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of a double-stranded oligonucleotide conjugated to N-acetyl-D-galactosamine (GalNAc) ligands. DCR-HBVS is a sterile solution of the siRNA (DCR-S219) at a concentration of 195 mg/mL in water for injection (WFI).
Placebo for DCR-HBVS
Sterile 9% saline for injection.

Locations

Country Name City State
Australia Monash Health Clayton Victoria
Australia St Vincent's Hospital Melbourne Fitzroy Victoria
Hong Kong Queen Mary Hospital (The University of Hong Kong) Hong Kong
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Seoul Metropolitan Government - Seoul National University Boramae Medical Center Soeul
New Zealand Clinical Site Auckland
New Zealand Middlemore Hospital Auckland
Thailand King Culalongkorn Memorial Hospital Bangkok
Thailand Srinagarind Hospital Khon Kaen

Sponsors (1)

Lead Sponsor Collaborator
Dicerna Pharmaceuticals, Inc.

Countries where clinical trial is conducted

Australia,  Hong Kong,  Korea, Republic of,  New Zealand,  Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Other To evaluate the preliminary antiviral efficacy of DCR-HBVS in participants with CHB by monitoring changes in serum HBsAg levels (all Group B and C participants)during and after single dose and 12 weeks of treatment with DCR HBVS. Proportion of participants achieving at least a 1-log reduction in HBsAg AND achieving a HBsAg level < 100 IU/mL at last scheduled visit Time to HBsAg loss (Kaplan-Mayer) Time to anti-HBs seroconversion 12 weeks
Other To evaluate the preliminary antiviral efficacy of DCR-HBVS in participants with CHB by monitoring HBeAg levels (HBeAg+ participants only) during and after single dose and 12 weeks of treatment with DCR HBVS. % of participants with HBeAg loss and anti HBe at last scheduled visit (if HBeAg positive at study entry) 12 weeks
Other To evaluate the preliminary antiviral efficacy of DCR-HBVS in participants with CHB by monitoring HBV DNA levels (all Group B and C participants) during and after single dose and 12 weeks of treatment with DCR HBVS. Proportion of participants achieving HBV DNA < 2000 IU/mL (if > 2,000 IU/mL at Baseline); and proportion of participants achieving PCR-nondetectable HBV DNA (if HBV DNA was detectable at Baseline). 12 weeks
Other To characterize the pharmacodynamics (PD) of DCR-HBVS on plasma levels of HBsAg and HBV in blood. Track post-treatment duration of any observed efficacy effects. 12 weeks
Primary Number of healthy volunteers with Adverse Events as assessed by CTCAE v5.0 Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings 4 weeks
Primary Number participants with non-cirrhotic chronic Hepatitis B with Adverse Events as assessed by CTCAE v5.0 Number of participants with abnormalities in vital signs, electrocardiogram (ECG), and clinically significant laboratory findings 16 weeks
Secondary To characterize the pharmacokinetics of DCR-HBVS in healthy volunteers by monitoring plasma pharmacokinetics profiles of DCR-S219 Measure the amount of DCR-HBVS excreted in urine 4 weeks
Secondary To characterize the pharmacokinetics of DCR-HBVS in healthy volunteers by monitoring through concentrations of DCR-S219 Measure the amount of DCR-HBVS renal clearance (CLR). 4 weeks
Secondary To characterize the pharmacokinetics of DCR-HBVS in participants with non-cirrhotic CHB by monitoring plasma pharmacokinetics profiles of DCR-HBVS. Measure the amount of DCR-HBVS excreted in urine 12 weeks
Secondary To characterize the pharmacokinetics of DCR-HBVS in participants with non-cirrhotic CHB by monitoring through concentrations of DCR-HBVS. Measure DCR-HBVS renal clearance (CLR). 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT03272009 - Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects Phase 1
Recruiting NCT01456312 - HBsAg Related Response Guided Therapy Phase 4
Terminated NCT01886300 - An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam N/A
Completed NCT00962975 - A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies Phase 1
Completed NCT01023230 - A Study to Assess DV-601 in Subjects With Chronic Hepatitis B Phase 1
Terminated NCT00460850 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. Phase 4
Completed NCT00536263 - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) Phase 3
Completed NCT03681132 - The Norwegian Nucleoside Analogue Stop Study Phase 4
Active, not recruiting NCT05473806 - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes Phase 4
Withdrawn NCT01179594 - A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. Phase 4
Recruiting NCT05057065 - A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Completed NCT04439539 - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection Phase 2
Withdrawn NCT03125213 - A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects Phase 2
Active, not recruiting NCT04782375 - Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B Phase 4
Withdrawn NCT05550519 - A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Early Phase 1
Completed NCT02693652 - A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine Phase 1/Phase 2
Enrolling by invitation NCT04160897 - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Active, not recruiting NCT02588937 - Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Phase 4
Completed NCT02612506 - Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers Phase 1
Recruiting NCT02327416 - A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) Phase 3